Thanks TG. One thing that I cannot understand is why the FDA required a Placebo Arm in a Trial of Severely Ill patients with historically high mortality rates. Maybe I'm wrong, but I would think the Control/Placebo Comparator would be the general population of severely ill patients who have not been treated with Leronlimab or whatever medicine was the subject of the study.

Further, if I were the patient's Doctor, I would request EIND before enrolling my patient in a Trial which gave them just a 66% chance of actually receiving the medicine I believed could help them, perhaps even save their lives.

Where am I going wrong?